San Fran biotech gets another blow to lead drug; Swiss biotech raises $49 million in Series A — with help from big venture

In the wake of Calithera Biosciences axing a third of its workforce in January over a failed Phase II trial with lead drug telaglenastat in patients with renal cell carcinoma, they just got slammed with the second half of a double whammy.

The South San Francisco biotech announced

Click to view original post